Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma.
Chiaro J, Kasanen HHE, Whalley T, Capasso C, Grönholm M, Feola S, Peltonen K, Hamdan F, Hernberg M, Mäkelä S, Karhapää H, Brown PE, Martins B, Fusciello M, Ylösmäki EO, Greco D, Kreutzman AS, Mustjoki S, Szomolay B, Cerullo V. Chiaro J, et al. Among authors: karhapaa h. Cancer Immunol Res. 2021 Aug;9(8):981-993. doi: 10.1158/2326-6066.CIR-20-0814. Epub 2021 Jun 8. Cancer Immunol Res. 2021. PMID: 34103348 Free PMC article.
Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events.
Jokimäki A, Hietala H, Lemma J, Karhapää H, Rintala A, Kaikkonen JP, Sunela K, Boman E, Jukkola A, Tiainen S, Seppälä J, Rönkä A, Hakkarainen H, Kärnä A, Iivanainen S, Koivunen J, Auvinen P, Hernberg M, Kuusisto M, Selander T, Kuittinen O. Jokimäki A, et al. Among authors: karhapaa h. Cancer Immunol Immunother. 2023 Oct;72(10):3337-3347. doi: 10.1007/s00262-023-03494-4. Epub 2023 Jul 24. Cancer Immunol Immunother. 2023. PMID: 37486396 Free PMC article.
Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy.
Vihinen H, Jokinen A, Laajala TD, Wahid N, Peltola L, Kettunen T, Rönkä A, Tiainen L, Skyttä T, Kohtamäki L, Tulokas S, Karhapää H, Hernberg M, Silvoniemi M, Mattila KE. Vihinen H, et al. Among authors: karhapaa h. Clin Lung Cancer. 2023 Jun;24(4):295-304. doi: 10.1016/j.cllc.2023.01.004. Epub 2023 Jan 24. Clin Lung Cancer. 2023. PMID: 36774235 Free article.